- Home
- STI vs GUTS Comparison
STI vs GUTS Comparison
Compare STI & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STI
- GUTS
- Stock Information
- Founded
- STI 2014
- GUTS 2010
- Country
- STI United States
- GUTS United States
- Employees
- STI N/A
- GUTS N/A
- Industry
- STI
- GUTS
- Sector
- STI
- GUTS
- Exchange
- STI NYSE
- GUTS NYSE
- Market Cap
- STI 51.2M
- GUTS 54.8M
- IPO Year
- STI N/A
- GUTS 2024
- Fundamental
- Price
- STI $0.09
- GUTS $1.22
- Analyst Decision
- STI
- GUTS Buy
- Analyst Count
- STI 0
- GUTS 1
- Target Price
- STI N/A
- GUTS $10.00
- AVG Volume (30 Days)
- STI 3.8M
- GUTS 272.1K
- Earning Date
- STI 06-06-2025
- GUTS 05-12-2025
- Dividend Yield
- STI N/A
- GUTS N/A
- EPS Growth
- STI N/A
- GUTS N/A
- EPS
- STI N/A
- GUTS N/A
- Revenue
- STI N/A
- GUTS $93,000.00
- Revenue This Year
- STI N/A
- GUTS N/A
- Revenue Next Year
- STI N/A
- GUTS N/A
- P/E Ratio
- STI N/A
- GUTS N/A
- Revenue Growth
- STI 32.73
- GUTS N/A
- 52 Week Low
- STI $0.08
- GUTS $0.87
- 52 Week High
- STI $3.25
- GUTS $7.89
- Technical
- Relative Strength Index (RSI)
- STI 36.91
- GUTS 52.03
- Support Level
- STI $0.08
- GUTS $0.87
- Resistance Level
- STI $0.17
- GUTS $1.17
- Average True Range (ATR)
- STI 0.02
- GUTS 0.11
- MACD
- STI 0.01
- GUTS 0.02
- Stochastic Oscillator
- STI 20.65
- GUTS 87.41
About STI SOLIDION TECHNOLOGY INC
Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a global IP leader in both the high-capacity anode and the high-energy solid-state battery.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.